From JPMA From the "JPMA Press Conference
1: Creating an environment for promoting innovation
Since announcing the progress of our policy recommendations in January 2019, we have continued our conversations with the government through public-private dialogue and advisory meetings. As a result, we believe that our requests have been incorporated into the policy and that measures for further industry-academia-government collaboration can be expected in the Kotta Policy 2019 and the next draft of the Health and Medical Care Strategy. We have also started to consider joint research with relevant stakeholders. We are already working on a highly concrete research plan and hope to begin the implementation phase in 2020.
In addition, the JPMA has been participating in the study of the "Action Plan for Promoting Genomic Medicine," which will begin in 2019. As a result, the first version of the action plan has been prepared. It is necessary to discuss more detailed parts of the plan in the future, and JPMA will continue to actively participate in the discussions.
Regarding the R&D taxation system, several requests from the industry side were reflected in the April 2019 revision. We will actively utilize the expanded tax system and communicate with the government to ensure that the time-limited measure is extended to 2021.
Japan Pharmaceutical Manufacturers Association Chairman Joji Nakayama
2: Appropriate evaluation of innovation
As part of our efforts to promote the proper use of pharmaceuticals, we have been co-hosting a seminar on drug resistance (AMR) with the Japan Medical Association, a public interest incorporated association, and working with the Council on the Proper Use of Drugs to create public awareness materials on polypharmacy. In the future, we will further strengthen and promote initiatives for proper use of drugs, such as holding media forums related to polypharmacy.
With regard to reform of the NHI drug price system, we have requested that the system be revised to appropriately reflect the medical value of pharmaceuticals, such as by improving the additional payment for new drug creation, etc. in preparation for the FY2020 NHI drug price reform. We will continue to study the "reorganization of the evaluation system for new drugs" and "establishment of an evaluation system that is easy for the public to understand" for the FY2022 NHI drug price reform. In addition, we will also work on "organizing the thinking behind the consideration of an all-generation social security system.
(From JPMA Newsletter, March 2020, No. 196, Top News)
Japan Pharmaceutical Manufacturers Association (JPMA) Japan Pharmaceutical Manufacturers Association (JPMA)
JPMA was founded in 1968 as an organization of R&D-oriented pharmaceutical companies with the aim of contributing to the improvement of health and welfare of people around the world through research and development of ethical drugs for use in hospitals, clinics, and other medical institutions.
JPMA is dedicated to the realization of patient-participatory medicine through activities to deepen understanding of pharmaceuticals and policy recommendations for the sound development of the pharmaceutical industry.
As a member organization of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), JPMA is engaged in global activities in cooperation with other organizations to address issues related to medicine and pharmaceuticals around the world.
Aiming to contribute to society through the development of new drugs Japan Pharmaceutical Manufacturers Association